


Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. (Original) A method for preparing a 6-oxo-14-hydroxy- Δ^7 -morphinane comprising oxidising a 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane for a time and under conditions sufficient to form a 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinane-N-oxide and converting the formed N-oxide to the 6-oxo-14-hydroxy- Δ^7 -morphinane.
2. (Original) A method according to claim 1 wherein the oxidation is carried out by treating the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane with hydrogen peroxide in the presence of a carboxylic acid.
3. (Original) A method according to claim 2 wherein the carboxylic acid is formic acid or acetic acid.
4. (Original) A method according to claim 3 wherein the carboxylic acid is formic acid.
5. (Original) A method according to claim 4 wherein the concentration of formic acid is 45% by weight formic acid in water.
6. (Currently Amended) A method according to ~~any one of claims 2 to 5~~ claim 2 wherein the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane is treated with a molar excess of hydrogen peroxide at a concentration of 50% by weight in water.
7. (Currently Amended) A method according to ~~any one of claims 2 to 6~~ claim 2 wherein the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane is dissolved in a mixture of the carboxylic acid and a solvent prior to the addition of the hydrogen peroxide.
8. (Original) A method according to claim 7 wherein the solvent is ethanol.
9. A method according to ~~any one of claims 1 to 8~~ claim 1 wherein the oxidation is conducted at a temperature below 50°C.
10. (Original) A method according to claim 9 wherein the temperature is about 20°C.

11. (Currently Amended) A method according to ~~any one of claims 1 to 10 including the additional claim 1 further comprising the step~~ of isolating the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinan-N-oxide before the conversion to 6-oxo-14-hydroxy- Δ^7 -morphinan.
12. (Original) A method according to claim 11 wherein the isolation step comprises neutralising the oxidation reaction mixture to a pH of about 7 by adding a base and collecting the N-oxide as a solid.
13. (Original) A method according to claim 12 wherein the base is selected from sodium or potassium hydroxide or potassium carbonate.
14. (Original) A method according to claim 13 wherein the base is sodium hydroxide.
15. (Original) A method according to claim 14 wherein sodium hydroxide is added to the oxidation reaction mixture at a rate which ensures that the reaction temperature reaches 55°C.
16. (Currently Amended) A method according to ~~any one of claims 1 to 15~~ claim 1 wherein the formed N-oxide is converted to the 6-oxo-14-hydroxy- Δ^7 -morphine by treating the N-oxide with a reducing agent.
17. (Original) A method for converting a 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinan-N-oxide to a 6-oxo-14-hydroxy- Δ^7 -morphinan comprising subjecting the N-oxide to reducing conditions to ring close the N-methyl group with the 14-hydroxy group forming an oxazolidine ring, and hydrolysing the ring closed oxazolidine product to form the 6-oxo-14-hydroxy- Δ^7 -morphinan.
18. (Original) A method according to claim 17 wherein the reducing conditions comprise treating the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinan-N-oxide with a Fe(II) based reducing agent and formic acid.
19. (Original) A method according to claim 17 wherein the hydrolysing step is performed using a strong acid selected from hydrochloric acid, sulphuric acid, hydrobromic acid or phosphoric acid.
20. (Original) A method according to claim 19 wherein the strong acid is hydrochloric acid.

21. (Original) A method of preparing a morphinane compound having a modified morphinane skeleton of structure (B)



said method comprising treating a 6-oxo-N-methyl-14-hydroxy- Δ^7 -morphinane-N-oxide with an Fe(II) reducing agent for a time and under conditions sufficient to ring close the N-methyl group with the 14-hydroxy group.

22. (Original) A method according to claim 19 wherein the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinane-N-oxide is treated as a slurry in methanol with a Fe(II) based reducing agent, whereby formic acid is added.

23. (Currently Amended) A method according to claim 21 ~~or~~ 22 wherein the Fe(II) reducing agent is FeSO₄.

24. (Original) A method for preparing N-alkyl or N-alkenyl 6-oxo-14-hydroxy-morphinanes comprising:


oxidising a 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane for a time and under conditions sufficient to form a 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinane-N-oxide,

converting the formed N-oxide to a 6-oxo-14-hydroxy- Δ^7 -morphinane,

reducing the Δ^7 double bond to form a 6-oxo-14-hydroxy morphinane, and


subjecting the 6-oxo-14-hydroxy-morphinane to N-alkylation to introduce the N-alkyl or N-alkenyl substituent.

25. (Currently Amended) A method according to ~~any one of claims 1 to 16 and 24~~ claim 1 wherein the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane is a compound of formula I:



where R is H, C₁-C₆ alkyl, benzyl or acyl.

26. (Original) A method according to claim 25 wherein the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane is a compound of formula I where R is H or CH₃.
27. (Original) A method according to claim 25 wherein wherein the 6-methoxy-N-methyl- Δ^6, Δ^8 -morphinane is a compound of formula I where R is H.
28. (Original) A method according to ~~any one of claims 1 to 24~~ claim 1 wherein the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinane-N-oxide is compound of formula II:




where R is independently selected from H, C₁-C₆alkyl, benzyl or acyl.

29. (Original) A method according to claim 28 wherein the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinan N-oxide is compound of formula II where R is H or CH₃.

30. (Original) A method according to claim 29 wherein the 6-oxo-14-hydroxy-N-methyl- Δ^7 -morphinan N-oxide is a compound of formula II where R is H.

31. (Currently Amended) A method according to ~~any one of claims 1 to 20 and 24~~ claim 1 wherein the 6-oxo-14-hydroxy- Δ^7 -morphinan is a compound of formula III:




wherein R is H, C₁-C₆alkyl, benzyl or acyl.

32. (Original) A method according to claim 31 wherein the 6-oxo-14-hydroxy- Δ^7 -morphinan is a compound of formula III where R is H or CH₃.

33. (Original) A method according to claim 32 wherein the 6-oxo-14-hydroxy- Δ^7 -morphinan is a compound of formula III where R is H.

34. (Original) An oxazolidine of formula IV:


BEST AVAILABLE COPY



IV

where R is H, C₁-C₆alkyl, benzyl or acyl.

35. An oxazolidine of formula IV according to claim 34 wherein R is H, CH₃ or benzyl.
36. An oxazolidine of formula IV according to claim 35 wherein R is H.
37. An oxazolidine of formula V:



V

where R is H, C₁-C₆alkyl, benzyl or acyl.

38. An oxazolidine of formula V according to claim 37 wherein R is H or CH₃.
39. An oxazolidine of formula V according to claim 38 wherein R is H.

BEST AVAILABLE COPY